Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
Espero BioPharma expands tecarfarin collaborative partnering effort
Elixirgen Therapeutics completes pre-Investigational New Drug meeting for COVID-19 vaccine candidate
Servier acquires Symphogen A/S
TVAX Biomedical wins FDA fast track designation for potential glioblastoma multiforme treatment
MyBio launches COVID-19 Antibody Test
INOVIO and IVI partner with Seoul National University Hospital to launch trial of COVID-19 vaccine
Novellus signs exclusive worldwide license agreement with Plexxikon for PLX8394 for solid tumours